TCHP
Checked 2026-09-09
Stage II-III HER2-positive breast cancer, neoadjuvant
One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Docetaxel Cytotoxic chemotherapy (taxane) | 75 mg/m² | IV | D1 | |
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 6 | IV | D1 | |
Trastuzumab Monoclonal antibody (anti-HER2) | 8 mg/kg loading then 6 mg/kg | IV | D1 | |
Pertuzumab Monoclonal antibody (anti-HER2, dimerisation domain) | 840 mg loading then 420 mg | IV | D1 |
Cycles
6, then HP to complete 1 year
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Recommended
Notes
- Diarrhoea is the limiting toxicity; carboplatin AUC 6 is often reduced to AUC 5.
- DESTINY-Breast11 (T-DXd × 4 then THP) reported a higher pCR than ddAC-THP and is entering guidelines.
Used in
Trials
Source
TRYPHAENA, Ann Oncol 2013; NCCN Breast Cancer
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Dose-dense AC → T
Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant
every 14 days × 4
APT (weekly paclitaxel + trastuzumab)
Stage I HER2-positive breast cancer, node-negative, tumour 3 cm or smaller
weekly × 12
THP (docetaxel + trastuzumab + pertuzumab)
HER2-positive metastatic breast cancer first line, then HP maintenance
every 21 days
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days